News - Gastro-intestinals, Licensing


Popular Filters

1 to 25 of 34 results

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan


Japanese drugmakers Otsuka Pharmaceutical and Takeda Pharmaceutical have entered into a co-promotion…

Asia-PacificGastro-intestinalsJapanLicensingMarkets & MarketingOtsukaPharmaceuticalTAK-438Takeda Pharmaceuticalsvonoprazan

Medigene signs collaboration with Falk Pharma for RhuDex

Medigene signs collaboration with Falk Pharma for RhuDex


German biotechnology company Medigene has signed an exclusive global license agreement with drugmaker…

BiotechnologyDr Falk PharmaGastro-intestinalsGermanyLicensingMedigeneNephrology and Hepatology

Ferring in up to 76 million euro deal with TxCell for IBD drug Ovasave

Ferring in up to 76 million euro deal with TxCell for IBD drug Ovasave


French biotech firm TxCell SA and privately-held Switzerland-headquartered Ferring International have…

BiotechnologyFerring PharmaceuticalsFinancialGastro-intestinalsLicensingOvaSaveTxCell

Ranbaxy and EPIRUS sign licensing agreement for Infliximab biosimilar

Ranbaxy and EPIRUS sign licensing agreement for Infliximab biosimilar


India's largest drugmaker Ranbaxy Laboratories (BSE: 500359) and EPIRUS Switzerland, a wholly-owned subsidiary…

Anti-Arthritics/RheumaticsBiosimilarsEPIRUS BiopharmaceuticalsGastro-intestinalsIndiainfliximabLicensingRanbaxy LaboratoriesRemicade

NovaMedica to distribute Aptalis products in Russia


Russian drugmaker NovaMedica, a joint enterprise between the Russian high-technology investment fund…

Aptalis PharmaEastern EuropeGastro-intestinalsLicensingMarkets & MarketingNovaMedicaPharmaceuticalRussia

Eisai expands marketing and supply agreement for Belviq worldwide

Eisai expands marketing and supply agreement for Belviq worldwide


Japanese drug major Eisai (TYO: 4523) has expanded the marketing and supply agreement between its US…


PeptiDream and Ipsen expand their peptide drug collaboration to treat endocrinologic disease


PeptiDream and Ipsen have expanded the scope of their April 2013 research collaboration and license option…


GlaxoSmithKline returns rights to vercirnon


US drug developer ChemoCentryx (Nasdaq: CCXI) says that partner GlaxoSmithKline (LSE: GSK), the UK’s…

ChemoCentryxGastro-intestinalsGlaxoSmithKlineLicensingNorth AmericaPharmaceuticalvercirnon

Sanofi US in deal to commercialize PA8140/PA32540


The US subsidiary of French drug major Sanofi (Euronext: SAN) has entered into a deal with US drugmaker…

AspirinCardio-vascularGastro-intestinalsLicensingNorth AmericaOmeprazolePharmaceuticalPozenSanofi

Nektar hedges bets on deal with AstraZeneca


Along with presenting second-quarter financial results, Howard Robin, president and chief executive of…

AstraZenecaFinancialGastro-intestinalsLicensingnaloxegolNektar TherapeuticsPharmaceutical

Second Genome in deal with Janssen on microbiome drug discovery in ulcerative colitis


Second Genome has entered into an agreement with Janssen Biotech, a subsidiary of US health care giant…

Gastro-intestinalsJanssenJohnson & JohnsonLicensingPharmaceuticalResearchSecond Genome

AbbVie and Alvine link up on investigational oral therapy for celiac disease


US drugmaker AbbVie (NYSE: ABBV) and privately-held Alvine Pharmaceuticals, a leader in celiac disease…

AbbVieALV003Alvine PharmaceuticalsGastro-intestinalsLicensingPharmaceuticalResearch

Positive Ph IIb results for SALVAT's tarafenacin in overactive bladder


Spanish drugmaker Laboratorios SALVAT and its South Koran partner Kwang Dong Pharmaceutical have released…

Gastro-intestinalsKwang Dong PharmaceuticalLaboratorios SALVATLicensingPharmaceuticalResearchtarafenacin

NPS Pharma regains rights to Revestive and Preotact from Takeda


USA-based NPS Pharmaceuticals (Nasdaq: NPSP) has re-gained the full worldwide rights from partner Takeda…

Anti-Arthritics/RheumaticsGastro-intestinalsGattexLicensingNatparaNPS PharmaceuticalsPharmaceuticalPreotactRevestiveTakeda Pharmaceuticals

Phenex in up to $135 million research collaboration with Janssen


Privately-held German drug discovery firm Phenex Pharmaceuticals has entered into an agreement with Janssen…

Anti-Arthritics/RheumaticsBiotechnologyGastro-intestinalsInflammatory diseasesJanssenJohnson & JohnsonLicensingPhenex PharmaceuticalsResearch

AstraZeneca gains rights to sell Ironwood's IBS drug in China


Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into an agreement with the USA's Ironwood…

Asia-PacificAstraZenecaGastro-intestinalsIronwood PharmaceuticalsLicensinglinaclotideMarkets & MarketingNexiumNorth AmericaPharmaceutical

Theravance in up to $63.5 million deal with Alfa Wassermann for velusetrag; RuiYi links with arGEN-X on MAb


USA-based Theravance (Nasdaq: THRX) and Italy headquartered Alfa Wassermann have entered into an exclusive…

Alfa WassermannarGEN-XARGX-109BiotechnologyGastro-intestinalsInflammatory diseasesLicensingOncologyPharmaceuticalRuiYiTheravancevelusetrag

Almirall gains rights for IBS drug linaclotide in Mexico


Spain's largest drugmaker Almirall (ALM. MC) says it has reached an agreement with USA-based Forest Laboratories…

AlmirallForest LaboratoriesGastro-intestinalsLicensinglinaclotidePharmaceuticalSouth America

AstraZeneca to get $250 million-plus from OTC Nexium deal with Pfizer


Anglo-Swedish drug major AstraZeneca (LSE: AZN) says it has entered into an agreement with Pfizer (NYSE:…


Salix and Alfa Wassermann expand rifaximin accord


USA-based Salix Pharmaceuticals (Nasdaq: SLXP) and Italy's Alfa Wassermann have entered into an exclusive…

Alfa WassermannGastro-intestinalsLicensingPharmaceuticalRespiratory and PulmonaryrifaximinSalix Pharmaceuticals

Research news: dolutegravir; TD-1211; and synaptic modulators


UK pharma giant GlaxoSmithKline (LSE: GSK) and Japanese drugmaker Shionogi (TYO: 4507) have reported…

Anti-viralsdolutegravirGalenea CorpGastro-intestinalsGlaxoSmithKlineLicensingNeurologicalPharmaceuticalRegulationResearchShionogiTD-1211TheravanceZonegran

Ferring Pharma gains rights for elobixibat from Albireo


Swiss drugmaker Ferring Pharmaceuticals has entered into a licensing agreement with Albireo AB, a Sweden-based…

AlbireoBiotechnologyelobixibatFerring PharmaceuticalsGastro-intestinalsLicensingPharmaceutical

Merck & Co to continue posting sales and profits under AstraZeneca partnership


US drug giant Merck & Co (NYSE: MRK) and Anglo-Swedish major AstraZeneca have amended the option agreement…

AstraZenecaFinancialGastro-intestinalsLicensingMerck & CoNexiumPharmaceuticalPrilosec

1 to 25 of 34 results

Back to top